%0 Journal Article
%T Multi-drug resistant Pseudomonas aeruginosa: a 2019-2020 single center retrospective case control study.
%A Yang AF
%A Huang V
%A Samaroo-Campbell J
%A Augenbraun M
%J Infect Prev Pract
%V 5
%N 3
%D 2023 Sep
%M 37520840
暂无%R 10.1016/j.infpip.2023.100296
%X Multi-drug resistance in the post COVID-19 world is a growing concern. The objective of this study was to describe temporal trends and explore independent risk factors for the isolation of multi-drug resistant (MDR) P. aeruginosa.<BR><B>UNASSIGNED: </B>This was a retrospective case-control study of patients with P. aeruginosa isolates recovered from January 2019 to December 2020. MDR P. aeruginosa was defined as non-susceptibility to at least one agent in three or more anti-pseudomonal antimicrobial categories.<BR><B>UNASSIGNED: </B>In total, 258 unique isolates were identified. Prolonged hospitalization (P<0.001), prior antibiotic use (P<0.001), and respiratory sources (P<0.001) were strongly associated with the presence of MDR P. aeruginosa. From 2019 to 2020, there was a decrease in the total number of P. aeruginosa isolates but a significant increase in the proportion of MDR P. aeruginosa isolates (P=0.015).<BR><B>UNASSIGNED: </B>Over a period that coincided with the COVID-19 pandemic, there was an increased proportion of MDR P. aeruginosa isolates from hospitalized patients. Improved identification of patients at risk for MDR P. aeruginosa could facilitate appropriate empiric antibiotic decisions like dual anti-pseudomonal therapy. The features of the COVID-19 outbreak that had a severe impact on patient care and that may have affected drug resistance in other respiratory pathogens should be explored.